These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20564841)

  • 1. [New oral anticoagulants: prospects].
    Fiessinger JN
    Rev Prat; 2010 May; 60(5):613-6. PubMed ID: 20564841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].
    Samama M; Conard J; Horellou MH; Le Flem L; Guinet C; Depasse F
    Ann Pharm Fr; 2010 Nov; 68(6):359-69. PubMed ID: 21073994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban.
    Drug Ther Bull; 2009 Oct; 47(10):116-20. PubMed ID: 19809086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Fundam Clin Pharmacol; 2012 Feb; 26(1):33-8. PubMed ID: 21851388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New oral anticoagulant drugs in cardiovascular disease.
    Ahrens I; Lip GY; Peter K
    Thromb Haemost; 2010 Jul; 104(1):49-60. PubMed ID: 20539909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New anticoagulants for the prevention of thromboembolism.
    Lepic K; Crowther M
    Curr Pharm Des; 2010; 16(31):3472-4. PubMed ID: 20858184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral anticoagulants for atrial fibrillation: Which one to choose?
    Ribowsky JH; Ismael AG
    Adv NPs PAs; 2012 May; 3(5):31-2. PubMed ID: 22670305
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
    Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
    Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
    Ufer M
    Thromb Haemost; 2010 Mar; 103(3):572-85. PubMed ID: 20135071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dabigatran: clinical pharmacology].
    Mismetti P; Laporte S
    Ann Fr Anesth Reanim; 2009 Sep; 28(9 Suppl):S8-14. PubMed ID: 19875005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of new anticoagulants in patients with cancer.
    Weitz JI
    Thromb Res; 2010 Apr; 125 Suppl 2():S30-5. PubMed ID: 20434001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
    Tripodi A; Palareti G
    J Intern Med; 2012 Jun; 271(6):554-65. PubMed ID: 22443239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement.
    Freyburger G; Macouillard G; Labrouche S; Sztark F
    Thromb Res; 2011 May; 127(5):457-65. PubMed ID: 21277622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
    Friedman RJ
    Orthopedics; 2011 Oct; 34(10):795-804. PubMed ID: 21956181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
    Steffel J; Braunwald E
    Eur Heart J; 2011 Aug; 32(16):1968-76, 1976a. PubMed ID: 21421599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dabigatran (Pradaxa): efficacy and safety].
    Rosencher N; Bellamy L
    Ann Fr Anesth Reanim; 2009 Sep; 28(9 Suppl):S15-22. PubMed ID: 19875000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.